DNA methylation or histone modification status in metastasis and angiogenesis-related genes: a new hypothesis on usage of DNMT inhibitors and S-adenosylmethionine for genome stability


SAHIN M., SAHIN E., GÜMÜŞLÜ S., ERDOĞAN A., Gultekin M.

CANCER AND METASTASIS REVIEWS, vol.29, no.4, pp.655-676, 2010 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 29 Issue: 4
  • Publication Date: 2010
  • Doi Number: 10.1007/s10555-010-9253-0
  • Journal Name: CANCER AND METASTASIS REVIEWS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.655-676
  • Keywords: Angiogenesis, Cancer, Metastasis, DNMT, S-Adenosylmethionine, HDAC, E-CADHERIN EXPRESSION, HUMAN BREAST-CARCINOMA, CELL LUNG-CANCER, UROKINASE PLASMINOGEN-ACTIVATOR, ENDOTHELIAL GROWTH-FACTOR, TUMOR-SUPPRESSOR GENE, NITRIC-OXIDE SYNTHASE, FACTOR-BINDING PROTEIN-3, CPG ISLAND METHYLATION, LYMPH-NODE METASTASIS
  • Akdeniz University Affiliated: Yes

Abstract

Metastasis is a leading cause of mortality and morbidity in cancer. This process needs angiogenesis. The biology underlying cancer, metastasis, and angiogenesis has been investigated so as to determine the therapeutic targets. Invasive and metastatic cancer cells have undergone numerous genetic and epigenetic changes, manifested by cytoskeletal changes, loss of adhesion, and expression of proteolytic enzymes that degrade the basement membrane. Additionally, in endothelial cells, some epigenetic modifications occur during the formation of angiogenesis. Researchers have used some methylation inhibitors, histone deacetylase inhibitors, or methylating agents (such as S-adenosylmethionine, SAM) against cancer and angiogenesis. Although they are effective to beat these diseases, each one results in differentiation or changes in genome structure. We review epigenetically modified genes related with angiogenesis and metastasis in cancer and endothelial cells, and suggest a new proposal. This hypothesis has discussed the importance of the usage of DNA methylation inhibitors together with SAM to prevent tumor progression and genome instability or changes resulting in additional diseases.